Literature DB >> 28863380

Effect of two andrographolide derivatives on cellular and rodent models of non-alcoholic fatty liver disease.

Erenius Toppo1, S Sylvester Darvin1, S Esakkimuthu1, Mahesh Kumar Nayak1, K Balakrishna1, K Sivasankaran2, P Pandikumar3, S Ignacimuthu4, N A Al-Dhabi5.   

Abstract

The prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) is increasing and there is an increasing interest in natural products to treat NAFLD. This study aimed to evaluate the hepatoprotective effect of andrographolide and two of its derivatives; in one the OH group at C-14 was removed and in the other OH groups at C-3 and C-19 were protected. Andrographolide (AN) was isolated from the aerial parts of Andrographis paniculata Wall. Isoandrographolide (IAN) and 3,19-acetonylidene andrographolide (ANA) were derivatized from AN. Drug likeness of the compounds was studied using DataWarrior. The effect of the compounds in ameliorating hepatic steatosis and lipotoxicity was assessed using palmitate-oleate induced steatotic HepG2 cell lines. In vivo efficacy of the compounds was assessed by using HFD fed rats. IAN showed comparatively high drug score and low irritability than AN. MTT assay indicated that the treatment with IAN had comparatively less toxicity than AN and ANA to HepG2 cells. The treatment with IAN significantly reduced the lipid accumulation and the leakage of LDH and transaminases, while the treatments with AN and ANA did not prohibit the leakage. In the in vivo experiment, the treatment with IAN showed comparatively better hepatoprotection by reducing the serum lipid, transaminases and ALP levels than with AN and ANA. Our results showed that IAN could be a promising lead to treat NAFLD with comparatively low toxicity and improved efficacy.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Andrographis paniculata; Fatty liver; Isoandrographolide

Mesh:

Substances:

Year:  2017        PMID: 28863380     DOI: 10.1016/j.biopha.2017.08.071

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease.

Authors:  Li-Sha Ran; Ya-Zeng Wu; Yi-Wen Gan; Hong-Lian Wang; Li-Juan Wu; Chun-Mei Zheng; Yao Ming; Ran Xiong; Yong-Lin Li; Shi-Hang Lei; Xue Wang; Xiao-Qing Lao; Hong-Min Zhang; Li Wang; Chen Chen; Chang-Ying Zhao
Journal:  J Nat Med       Date:  2022-09-17       Impact factor: 3.192

2.  microRNA-378b regulates ethanol-induced hepatic steatosis by targeting CaMKK2 to mediate lipid metabolism.

Authors:  Ying-Zhao Wang; Jun Lu; Yuan-Yuan Li; Yu-Juan Zhong; Cheng-Fang Yang; Yan Zhang; Li-Hua Huang; Su-Mei Huang; Qi-Ran Li; Dan Wu; Meng-Wei Song; Lin Shi; Li Li; Yong-Wen Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 3.  Application of herbs and active ingredients ameliorate non-alcoholic fatty liver disease under the guidance of traditional Chinese medicine.

Authors:  Zhijia Zhou; Jinghao Zhang; Liping You; Tao Wang; Kaixia Wang; Lingtai Wang; Xiaoni Kong; Yueqiu Gao; Xuehua Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-20       Impact factor: 6.055

4.  Heat shock protein 70 promotes lipogenesis in HepG2 cells.

Authors:  Jielei Zhang; Nengguang Fan; Yongde Peng
Journal:  Lipids Health Dis       Date:  2018-04-10       Impact factor: 3.876

5.  Andrographolide Exerts Antihyperglycemic Effect through Strengthening Intestinal Barrier Function and Increasing Microbial Composition of Akkermansia muciniphila.

Authors:  Hongming Su; Jianling Mo; Jingdan Ni; Huihui Ke; Tao Bao; Jiahong Xie; Yang Xu; Lianghua Xie; Wei Chen
Journal:  Oxid Med Cell Longev       Date:  2020-07-23       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.